{"url":"https://lda.senate.gov/api/v1/filings/d092686d-10d3-453a-95b5-03f493731524/?format=json","filing_uuid":"d092686d-10d3-453a-95b5-03f493731524","filing_type":"RR","filing_type_display":"Registration","filing_year":2017,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.senate.gov/filings/public/filing/d092686d-10d3-453a-95b5-03f493731524/print/","filing_document_content_type":"text/html","income":null,"expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Madeline Scherwitzky","dt_posted":"2017-04-10T16:35:37-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":"United States of America","registrant_address_1":"600 LEE ROAD SUITE 100","registrant_address_2":null,"registrant_different_address":null,"registrant_city":"WAYNE","registrant_state":"PA","registrant_zip":"19087","registrant":{"id":401104361,"url":"https://lda.senate.gov/api/v1/registrants/401104361/?format=json","house_registrant_id":43561,"name":"ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)","description":"Specialty Pharmaceutical Company","address_1":"600 LEE ROAD SUITE 100","address_2":null,"address_3":null,"address_4":null,"city":"WAYNE","state":"PA","state_display":"Pennsylvania","zip":"19087","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"MADELINE SCHERWITZKY","contact_telephone":"+1 425-523-8565","dt_updated":"2022-04-06T16:06:32.276341-04:00"},"client":{"id":201602,"url":"https://lda.senate.gov/api/v1/clients/201602/?format=json","client_id":12,"name":"ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)","general_description":"Registrant's name change from Egalet Corporation to Zyla Life Sciences","client_government_entity":false,"client_self_select":true,"state":"PA","state_display":"Pennsylvania","country":"US","country_display":"United States of America","ppb_state":"PA","ppb_state_display":"Pennsylvania","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2017-02-20"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Abuse Deterrent Formulation(ADF)Legistlation","foreign_entity_issues":null,"lobbyists":[{"lobbyist":{"id":66526,"prefix":null,"prefix_display":null,"first_name":"CARA","nickname":null,"middle_name":"D","last_name":"MOON","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Abuse Deterrent Formulation(ADF)Legistlation","foreign_entity_issues":null,"lobbyists":[{"lobbyist":{"id":66526,"prefix":null,"prefix_display":null,"first_name":"CARA","nickname":null,"middle_name":"D","last_name":"MOON","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[]},{"general_issue_code":"MED","general_issue_code_display":"Medical/Disease Research/Clinical Labs","description":"Abuse Deterrent Formulation(ADF)Legistlation","foreign_entity_issues":null,"lobbyists":[{"lobbyist":{"id":66526,"prefix":null,"prefix_display":null,"first_name":"CARA","nickname":null,"middle_name":"D","last_name":"MOON","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}